QAK 423Alternative Names: QAK423
Latest Information Update: 11 May 2006
At a glance
- Originator Novartis
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Jan 2006 Discontinued - Phase-I for Chronic obstructive pulmonary disease (unspecified route)
- 03 Jan 2006 Discontinued - Phase-I for Asthma (unspecified route)